Mary Wilkinson

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Minetta C. Liu, Peter G. Shields, Robert Warren et al. · Journal of Clinical Oncology · 2009 · 318 citations · Full text

Medicine, Oncology, Chemotherapy +16

The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy

Thomas A. Davis, Mark Kaminski, John P. Leonard et al. · Clinical Cancer Research · 2004 · 152 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Performance Evaluation of the ADVIA 2120 Hematology Analyzer: An International Multicenter Clinical Trial

Neil Harris, Josep M. Jou, Gianluigi Devoto et al. · Laboratory Hematology · 2005 · 105 citations · Full text

Medicine, Hematology, Biosensors +12